How to run a phage therapy center from your academic lab — Podovirus podcast
54 min

How to run a phage therapy center from your academic lab

The conversation

Episode notes

Daria van Tyne, an associate professor of medicine at the University of Pittsburgh, explains how her research lab built a compassionate use phage therapy program. She describes the practical choices that helped the team handle growing requests while using patient samples to investigate questions that laboratory screening alone cannot answer.

Van Tyne describes batching susceptibility testing weekly and prioritizing phages already prepared for treatment, reducing the need to manufacture a new preparation for every patient.

Her team used genome sequencing to check preparation identity and purity alongside toxin and sterility testing, and remade batches when sequencing revealed contamination with other phages.

Patient samples helped generate research questions, but differences among patients and treatments limited conclusions, while the relationship between laboratory susceptibility results and patient benefit remained unresolved.

Episode timeline

  • 0:00 Introduction and the first phage therapy cases
  • 6:54 Batching requests and preparing phages for multiple patients
  • 16:21 Manufacturing, quality checks and storing phages for reuse
  • 31:19 Collecting patient samples to investigate treatment
  • 41:00 Why susceptibility assays still need validation
  • 48:19 Future hopes for trials, personalized treatment and sharing

Learn more

Transcript

AI-transcribed and edited for readability. May contain errors or omissions; check the recording for exact wording.

Select a word or timestamp to listen. Use arrow keys to move between words.

  1. Joe Campbell

    Today we have Daria van Tyne from UPMC Medical Center and we're really excited to talk to her. We've been talking to a bunch of people who are actively involved in phage therapy to get their sense of how they got there and where they are and where they hope to be. So, Daria, do you wanna quickly introduce yourself?

  2. Daria van Tyne

    Yeah, sure. So I am an associate professor of medicine at the University of Pittsburgh. I run a research lab in the division of infectious diseases. I'm a PhD, but I work with a bunch of doctors at UPMC. It's my physician colleagues' experience with antibiotic-resistant infections and their openness to using phage to treat those infections that has driven both my research program as well as our clinical efforts in phage therapy.

  3. Joe Campbell

    Okay, great. Maybe you can dig down a little deeper, like the first few cases. How did they come about?

  4. Daria van Tyne

    Yeah, definitely. So I, moved to Pitt in 2018 from my postdoc, so this was my first faculty position. And I came to Pitt with a real interest in phage and phage therapy. I tell people I was phage poor. I had no phages when I got here, just a lot of interest in phages. When I was being recruited the year before I came here,

    I remember one of my recruitment visits actually coincided with the treatment of Mallory Smith with phage therapy. And so the faculty that took me out to dinner were some of the same physicians that were involved in her treatment and care. And so I came talking to them about phage already, and they came to dinner saying, Oh, you know, we're living this right now with this patient who's being seen and cared for here at UPMC.

    That was sort of, you know, early inspiration for trying to start some phage therapy in earnest here. But for me, I came really interested in phage, but I needed to find some phages to get something going. So I asked my colleagues here in the division to give me bacterial isolates that were like the kinds of bugs that they might want to treat with phage therapy. So I got a lot of antibiotic-resistant Pseudomonas and some Burkholderia and some Achromobacter and Steno.

    And I mean, sort of, you name it. But with these organisms, these strains from my colleagues, we then sourced wastewater from a hospital in Pittsburgh, not the UPMC hospital I'm at, but a different hospital in the area, as well as municipal wastewater, and just started fishing for phages. And I would say the only thing about what we did

    that might be different from what other people do is that we used the multidrug-resistant clinical isolates as the sort of bait on the fish hook. And that helped ensure that the phages that we got back out were clinically relevant or could be used to treat these bugs that were causing infections in the patients here. So, you know, over several years, and with a lot of, like, mostly undergraduate effort, we slowly built a library of phages targeting these kinds of pathogens.

    And it's all been driven by the clinical need of what our physician colleagues tell us are the bugs that are causing infections in their patients that they would like to treat with phage if there were phages available. And so the first case I was involved in treating was in 2020, in the fall of that year. And it was a patient with cystic fibrosis who had had a lung transplant and had been persistently colonized with Burkholderia multivorans and did quite well after transplant.

    But unfortunately, a couple of years after her transplant, she became ill again with the same Burkholderia strain that had been colonizing and infecting her for over a decade. So the physicians, you know, without anything in the antimicrobial armamentarium available to treat this patient, reached out for phage. And we got her isolates and tried to find phage, but we didn't have any Burk-targeting phages. But her isolates also were sent to Ben Chan at Yale, and he was able to find a phage that was active on her isolate.

    And so Ben, to his credit, worked through the night, uh, and within, like, a week to ten days, had a phage that was manufactured on the patient's own isolate and was sent back here to Pitt to treat this patient, that first patient. My role was literally just sort of observing, but because we were here, the patient's family very graciously consented to collection of biospecimens from the patient.

    So we were able to sample her before, during and after she received phage therapy. And you know, in my role as a researcher, that's what I like to do is observe things that are happening and do experiments in the research lab to try and generate knowledge. And so just trying to document on a microbiologic level what was happening to this patient as she received phage therapy was the first kind of experience that I had with treating patients.

    And of course, very soon after we treated that patient, there was a second patient, this time with an Enterococcus infection where again, we got involved looking for phage for the patient, not having any Enterococcus phages. And then contacting a colleague, who in that case was Breck Duerkop at the University of Colorado, who was again very generous with his own phages, sending us phages that he identified as active on the patient's isolate.

    In that case, we manufactured the phage in my lab following, protocols and advice from Ben Chan. And that was the first patient where we actually made the phage for the patient in our lab ourselves. So we treated two patients in 2020, I think another two patients in 2021, I think we did four patients in 2022. And then in January of 2023, I gave a seminar at IPATH, I visited UCSD and gave a talk at IPATH, and basically that kind of opened the floodgates.

    I think from that point forward, we started to get referrals from IPATH. Um, and so starting in 2023, we've been treating now dozens of patients each year with phage therapy, all under compassionate use and all with phages that, um, we're manufacturing here in our lab.

  5. Jessica Sacher

    It's incredible that you have set up a system in your lab without making your research stop. You still publish papers on research. And I just feel like that needs to be highlighted, how hard that is. Because having been on the ground making phages in Australia, we pretty much had to convert our lab into a phage-making facility. And that was the hardest thing to actually not have it consume all of our time.

    So I would love to hear how you have managed that, or maybe how it's evolved, too. Like, I imagine in the beginning, it started out being more all-encompassing. But have you been able to scale that up? If so, how?

  6. Daria van Tyne

    Yeah, that's a good question, and one I get a lot. So I'll say first that we've tried to optimize all the workflows for efficiency. So it takes an incredible amount of time and a ton of effort to go from, like, a request for phage therapy to like, here's your phage, give it to your patient. And so there are parts of that process that we control and parts of that process that the physician, the treating physician, controls.

    So the parts of that process that we control, like the susceptibility testing, the phage manufacturing, formulation, testing of the formulation and dispensing, all of that we can control. And so, for example, for phage susceptibility testing, right, we have libraries of the phages that we have for a particular pathogen. And it probably takes maybe 25 to 30 percent of a technician's time each week to perform susceptibility testing. But we receive isolates all the time.

    But, you know, on Mondays, like today's a Monday, this morning I sent the technician a Slack message and said, Here are about eight or ten isolates that need to be tested for phage susceptibility this week. And those are all the isolates that we received last week.

    So it's not like a constant adding more and more to, like a ticker, right? It's like a batching workflow. So, like, we perform susceptibility testing on the isolates we received last week, and the isolates we received this week are going to get tested for susceptibility next week. So we have like a sort of a weekly queue system, which works well for us. For the manufacturing side, that's the other big one, right? It can be incredibly difficult to manufacture phage for a patient. So the way that we've tried to optimize it is that we try to only pick good phages.

    So I tell students in the lab when they're isolating phages and they're getting really disheartened because, like, their phage is not passaging well. And they're not able to, like, pick a plaque and then get a good-looking titer from that plaque pick. I say, just let it go. That's not a phage that we want because, like, for phage therapy, we want the lean, mean killing machines that can infect and replicate. You know, basically, if an undergraduate messes up the experiment but the phage can still replicate and still infect and still show a titer in that

    scenario, that's the phage that I want for phage therapy, the, like, undergrad-proof phage. So just by nature of that kind of selective process of ending up with the phages we use for therapy, we're pretty selective and we only pick phages that can replicate at really high efficiency. Also, for Pseudomonas, which is like the vast majority of the phage therapy requests that we get.

    We're using phages that replicate well on PAO1, a laboratory strain that FDA is okay with us using to manufacture phage. And so if we're manufacturing a super efficient phage on a laboratory strain of Pseudomonas, then we can generate enough phage to treat lots of different patients. So we've tried to move as much as we can away from manufacturing phage on the patient's own isolate.

    So moving to manufacturing hosts for these phages gives us the ability to use one prep of phage to treat lots of different patients. And we also have now gotten to the point where we've manufactured, you know, therapy-ready preps of dozens of phages. And they sit in the refrigerator in glass vials. And when we're doing the susceptibility testing, you know, we start with a spot test where you're just spotting lysate on the strain.

    And from the results of that spot test, you pick the phages that you want to titer to say, okay, I saw clearing on a spot test, but this is actually like phage replication. And when we pick the phages to titer, we're thinking about what we have already manufactured for therapeutic use. So we're not titering all the phages that show clearing in a spot test. We're only titering the phages that we've manufactured and have ready.

    And as we've gone more and more, we've noticed that, like, the groups of phages that we're putting together to treat a patient, those phages tend to be active on strains. Like if a strain is susceptible to one of those phages, it's susceptible to the other ones as well. So we're at a point now where most of the patients that we're treating, at least with Pseudomonas infections, we're treating with like a minimum number of cocktails of different phages.

    So, I think those are all kind of ways that we've tried to make the process a little bit more efficient. It still does take a lot of time, but it's a labor of love. And again, like, I find a lot of fulfillment in the clinical side because, like, I'm not a doctor. But I got into this kind of research because it was highly translationally relevant.

    But at my core, I'm still a researcher, so I'm still there in the lab, like, asking questions and trying to design experiments and having my trainees pursue research questions that are really fueled by this clinical work. And so right now, I can't see one without the other, and so for as long as I can, I'm gonna pursue both.

    Love that.

  7. Joe Campbell

    So let's go back to the first couple of cases. Who was interacting with the FDA? Was it you or the physicians or both? And has that evolved over time?

  8. Daria van Tyne

    Yeah, so it's all of us. Because my lab's the manufacturer of the phage for these compassionate use cases, right? I'm one of the people involved. Each case has a treating physician, so it can be a physician here at UPMC for our local patients, or, you know, a local treating physician if it's a patient at a different center. And they're the sponsor-investigator. They're the one that's actually submitting the IND application.

    Those first couple of cases that we did were usually patients that were very ill and we were applying for an emergency IND, which is asking the FDA to reply within 24 hours to the request. And so for most of those cases, what would happen is we would send the IND application and then the FDA would request that we all get on the telephone together, which always happened on, like a Friday at six p.m.

    You'd have to drop everything and like, call the FDA, and be on a conference call with, you know, product reviewers and CMC reviewers. That kind of felt like a grilling session. Like, you know, I would liken it to, like, my qualifying exam for my PhD. Like, that's how nervous I would feel with these FDA reviewers on the phone call, asking us lots of questions about the treatment plan, about the phage that we manufactured, about, like, the aspects of the case. And we would do our best to answer those questions. And I would have to say, like, you know, the process was a little nerve-racking, but every single request that we made to the FDA to treat a patient with phage in that kind of scenario was always approved.

    They never denied any of the IND requests that we made, and so those were like the early experiences. More recently, we've hired a program manager, which is fabulous because she takes care of a lot of the administrative legwork. And for UPMC patients, she's the one that submits the IND applications on behalf of the treating physician, and she makes sure that it's done correctly.

    Because you can imagine, like busy doctors are forgetting stuff and making errors all the time, so having somebody like double checking their work is really fabulous. And also because now we've switched from eINDs to mostly single-patient INDs, where we're asking the FDA for permission to treat a patient with phage, but the patient is, like, not critically ill and they have the ability to wait before we initiate treatment.

    FDA has 30 days to respond in those cases. And now most of our communication is over email, so they'll review the application and then send us written comments and questions that we can then reply to and respond over email. So, my interactions with the FDA, like, I have a lot of them, but they're much less anxiety-inducing than they used to be. I think the FDA has always been like a very important step in the process.

    I don't think that they've put up any barriers for us to be able to give phage to patients, and, if anything, they're actually facilitating now the way that we are doing phage therapy. And I think that their advice has definitely, or their sort of regulatory process has evolved as the field has evolved. And I've been very like, happy to see that they've evolved in the sort of things that they require and the questions that they ask.

    They're all physicians and scientists, just like we are, and so they have the same kind of curiosities that we do about, like, what is happening here? And in the compassionate use scenario, all of their criticism and comments, and questions come from the standpoint of wanting to make sure that the patient is gonna be safe, that they're not going to be harmed by this experimental therapy.

    And I think that they execute on that mission very well, even though sometimes it does make some more work for us. I feel like the work is always justified because it's from a place of trying to ensure the safety of the patient.

  9. Jessica Sacher

    I'm really curious. On the quality side, for the final batch, how have you needed to prove that it is clean? And if you have students, what level of students or technicians is doing that work? And how do you trust it basically?

    How much documentation versus you being there? Like, how have you made that work?

  10. Daria van Tyne

    Yeah, that's a good question. So, the phages themselves are not manufactured by students. I have a laboratory manager, who takes on most of the manufacturing and has been, you know, been here for a while and is sort of a trusted person to do the manufacturing. But it's not just the manufacturing being done, you know, by somebody that has plenty of experience and whose work you would trust.

    But it's also like how we test what comes out and convince ourselves that it is what we want it to be and that it's safe. So the first thing I would say is that we now use whole-genome sequencing to QC all of our phage therapy-ready preps. So as soon as a phage batch gets manufactured in the lab, we extract DNA from it and send it for sequencing.

    And that simply tells us the identity and the purity, to make sure that it's the phage that we intended to manufacture. And there's no trace of cross-contamination or other phages that have mixed in there. And we have found evidence of that before, and when that happens, we go back and make it again. So we have a QC just for identity and purity using whole-genome sequencing.

    Beyond that, we have to test endotoxin levels on all of the preps that we make. So we do like the LAL assay to quantify how much endotoxin is in the preps. And then for Pseudomonas phages, there's Pseudomonas exotoxin A that we also measure using, like an ELISA-type kit. Beyond that, we do sterility testing. We send a formulated phage to a company that does USP 71 sterility testing.

    But the final layer of like sort of check is actually me. So I'm the one that does all the formulation and that facilitates the sort of testing at the end. So, like you said, like, how do you make sure that you trust the process? I mean, I guess I don't trust anybody else to do it, so I do it myself.

  11. Jessica Sacher

    So you're diluting it into saline or something like that, and you are submitting the aliquots to this company for sterility and doing the endotoxin testing?

  12. Daria van Tyne

    Yeah, that's right. So we, formulate in PBS, usually with some magnesium sulfate, which we hope helps keep the phage stable. And then it gets aliquoted and sent for sterility testing. I should say also that we formulate in PBS with mag sulfate, and then that gets sterile-filtered. So, like the last thing that happens before it gets aliquoted is it goes through a 0.2-micron filter.

    And hopefully because of that, we've had good success with sterility testing and we haven't had any batches come back as positive in the USP sterility test yet. Knock on wood.

  13. Jessica Sacher

    Exactly. So, Daria, are you the one doing that every week, or how often? What day is your manufacturing day? Or, sorry, your formulation day? Like, what does that feel like for you?

  14. Daria van Tyne

    Yeah, I am the one, so I take the role of manufacturer very seriously, right? Like, if I'm making something that's going to go and be like, administered intravenously to patients, right? I wanna be the one to own it and take responsibility for it. How does it actually happen? It's usually between like 8:30 and 9:00 a.m. because that's when I'm in the lab in the morning.

    And actually, the, you know, grad students and postdocs, right? The lab is pretty empty and dead until at least 9:00 or 9:30 a.m. But I get up early because I have small children and I drop my child at preschool at like 8:00, and then I come straight to the lab. So I'm here, I have the lab to myself. And that's when it's easiest to get the time and focus needed to be formulating phage for patients.

  15. Jessica Sacher

    Yeah, oh, I have so many questions. To stay in the nitty-gritty, before we zoom out, like, in terms of how you clean them up, what's your process these days? Especially thinking about how many phages are you using? Are you using single-use methods or do you have to kind of use equipment like ÄKTA pure to actually purify these phages?

  16. Daria van Tyne

    Yeah, my technicians, you know, heard about the ÄKTA pure from your work, Jess, and were very excited about it, and I was excited about it too. And then I was like, Well, where can I find a couple tens of thousands of dollars to buy an ÄKTA pure? So we're old school and cheap. I did purchase an ultracentrifuge, a used ultracentrifuge so that we could band. So our preferred method for manufacturing right now is to, however, we need to do it, whether it's in liquid or in soft agar overlay, to just get a bunch of phage, right? So whatever conditions we need, whatever MOI we need, and whatever format we need to try and generate like ten to the thirteenth PFU total of phage, we do that and then we concentrate it to get the volume lower, and then we're ultracentrifuging using cesium chloride.

    And I think that's my preferred method for manufacturing, just from a purity standpoint. Before we were doing that, we were just prepping in liquid and then concentrating and then doing like an octanol extraction, dialyzing out the octanol, and then hoping that we had a very high titer of, you know, a purified lysate that we could then dilute quite a bit. And, you know, hope that we're diluting out impurities, you know, more than we're diluting the phage. But more recently, you know, I think that doing cesium chloride banding, compared to that, is a preferred method. Obviously, it raises issues of toxicity with the cesium, so, of course, after we band, we dialyze extensively to remove the cesium.

    But yeah, cesium chloride and ultracentrifugation right now is our preferred method. Yeah, every phage has been a little bit different and it's always an odyssey. Unfortunately, Nate, the lab manager, is like banging his head against the wall trying to manufacture, you know, a phage right now that previously manufactured fine, and this time around, it's giving us more trouble. So there are these struggles,

  17. Jessica Sacher

    Yeah, literally the problem of my life.

  18. Daria van Tyne

    Exactly. So, yeah, we're not special, we're not any different than anybody else that's trying to make phage, that's having these problems. All I would say is maybe that we've started with more phages and our volume is such that we get so many requests that only 15 to 20 percent of them end up getting phage therapy. But, you know, starting with a large number, 20 percent of a large number is still a decent number.

  19. Joe Campbell

    So you mentioned earlier that you have some frozen preps. Is the process you were talking about what you do when you have to make a new phage, when you have to make a phage anew? What's the process that you do when you come in on Monday, or whenever it is that you do the testing for a phage you haven't banked already

    and that's one of the phages that's going to be involved in the therapy?

  20. Daria van Tyne

    Yeah, so there's two levels to it, right? So we have individual phages that have been manufactured and are sitting in glass vials. So we can formulate, you know, mix whichever phages were active against a patient's isolate, at, you know, a desired potency, which is usually about one times ten to the ninth PFU per dose. Though, if the endotoxin is low enough, we might go higher.

    Though, we don't usually go higher than one times ten to the tenth, so we're in, like, we're between one times ten to the ninth and one times ten to the tenth PFU per dose. So we can formulate the phage, but also when we formulate phage, you know, we're mixing three phages together to make a three-phage cocktail for a particular patient.

    But if the next patient's isolate is susceptible to those three phages and we have the cocktail, right, we have the cocktail that's left over, we will also, you know, use unused doses from the first patient to treat the second patient. And you can imagine in that scenario, for the second patient, everything goes faster. So, you know, once the physician has a treatment plan, the CMC details of the actual phage, the phage prep itself are the same.

    Because I made the phage the same way and formulated them the same way. The sterility testing, if it's within six months, is the same. And so being able to use, you know, not just the manufactured phages for multiple patients, but the actual cocktail that we've formulated on multiple patients as well is another way that we can make this process more efficient.

  21. Joe Campbell

    Titers dropping or anything like that, or

  22. Daria van Tyne

    We check the potency every six months. We also recheck sterility every six months for everything that we formulated, and we don't see a big drop. One tip that I don't know is all that widespread is that when we aliquot the phages, we aliquot them in like multiple 1 cc doses. And we use protein low bind tubes.

    So these are tubes that have like a coating on them that is supposed to make it so that any protein isn't gonna bind. We found, like in conventional tubes and conventional like Eppendorf tubes or conventional plastic, right? The phages stick. They're kind of sticky, so they'll adsorb to the plastic and that will make the titer go down over time. But using these protein low bind tubes, I've been pleasantly surprised at the stability. In glass vials, they seem to be pretty stable as well.

    We do see some titer drop over time and we check every six months and adjust the sort of formulation accordingly. But yeah, with these protein low bind tubes, they seem to be pretty stable.

  23. Jessica Sacher

    That's a great tip. That's exactly what I was gonna ask about, because we were not able to keep using the same phage for multiple people in Australia. We only had a 30-day window where they would allow us to use that prep unless we proved that it was stable longer. That was something we were gearing up to be able to do for all of our phages.

    So, that's good to know. Is that just that the FDA is fine with a sterility test that's six months old? Like, they kind of gave you that timeframe.

  24. Daria van Tyne

    Yeah, yeah, it was based on their advice to sort of repeat the sterility and to also check the potency at a pace of roughly every six months. Yeah, and I think that that seems reasonable, right? I think testing more frequently, you know, if you're gonna do a clinical trial, obviously more frequent testing would probably be warranted. But for compassionate use, I think checking every six months is appropriate.

  25. Jessica Sacher

    I also wonder, I know that you mentioned at the phage DC conference, I keep calling it phage DC. It's not the name of the conference. It was in…

  26. Daria van Tyne

    That's not a bad name, though. Maybe we could rebrand it.

  27. Jessica Sacher

    What was the name? No one can… It's a mouthful.

  28. Daria van Tyne

    It really was.

  29. Jessica Sacher

    But anyway, so Phage DC, you gave like the keynote and it was just so incredible to hear, like this entire story, which is kind of why, yeah, we really wanted to keep talking to you. And one of the things that I thought was really striking is when you had that graph of all your phages, like which ones were the best, kind of thing? And you did see this sort of like curve, almost like 80/20 rule.

    Or roughly, it seemed like from afar that most of the cases are susceptible to, like, you know, a small number of phages. And so you can kind of just get really good at making those really good phages and really help yourselves. And I saw that your top one was such a great Pseudomonas phage. It sounds like that would really help.

  30. Daria van Tyne

    Yeah, so the phage that we've used very frequently, we actually passaged it in the laboratory. It sort of evolved it in the lab. I think it speaks to the biology of the organism. I think for Pseudomonas, which again is like the number one problem bug, that we get. Over half of the requests for phage susceptibility testing and phage therapy that we get are for Pseudomonas. I do think that there's like a relatively small number of phages that would give you good coverage.

    I mean, I'm thinking also of like, just in the Bollyky lab, right? The paper, maybe earlier this year or last year, about the complementarity groups, right? Showing that with a small number of phages, you could get very good coverage of like a large swath of clinical isolates. But that may not be true for all organisms, right? There are others that are different.

  31. Joe Campbell

    So when you say that the phage isn't the same, is that something that happened because you were deliberately passaging it in a way you thought would make a more effective killing machine? Or was it just that you've grown it in the lab several times and it's drifted?

  32. Daria van Tyne

    Yeah, it's, I think it's the latter. So we didn't try to make it any better. But in the course of, like, isolating it, passaging it in the lab again, with undergraduates, kind of putting it through our gauntlet, where only the strong phages survive, what came out and what we sequenced of what came out, you know, was not the same as the publicly available genome for this phage.

    So I don't know if that sort of evolution and drift happened after it came into our lab. But you raise a very important point, which is that phages are alive-ish and they can evolve. And so for things like a patent application, if you want to patent a phage, you submit the genome sequence of the phage. And it's kind of an open question: How different does the sequence have to be before you would say it's not the same phage anymore?

    We've noticed that, because now we sequence more and more, right? Because that's my preferred method for QC. I think it's the most reliable QC method for assessing identity and purity of the phage. So as we sequence more and more, we do find some phages are just locked in. And it's probably because we're always growing them on the same propagation host, right?

    But for some phages, we sequence them over and over and over again over the course of sort of manufacturing and growing them more and more, we don't see any mutation, like not a one in the genome. And then for other phages, we do see that they do pick up some mutations here and there. We haven't done a lot of mixing phages together in like an Appelmans kind of approach.

    where you're trying to get phages to, like, recombine with one another and generate like entirely new phages. But we at least have the tools where we can, like, see that and understand if that's happening or not, which I think is an important piece here.

  33. Jessica Sacher

    Yeah, I would love to talk about the data collection side of your compassionate use cases. How common is it's like the first one, where you were able to collect before, during and after samples, and are you routinely doing that these days?

  34. Daria van Tyne

    Yeah, for all the patients here at UPMC that receive phage therapy, we invite them to enroll in a biorepository to provide biospecimens for research. So we explain to the patient and make it clear that it's two separate consent processes. And so they first consent to receive phage therapy, which they will get no matter what. And then if they want to participate in research, they can do a separate consent to collect biospecimens from them.

    And it looks like a little bit of extra blood. Usually some combination of urine, rectal swab, and then if it's a patient that's getting inhaled phage therapy, we'll get sputum if they can make sputum. And then, like a throat swab and a nasal swab. So it's a decent amount of specimens. Most of the patients, though, that receive phage therapy, are used to being poked and prodded a lot, I think, because they're usually medically complex and have a lot of experience with medicine.

    So all the patients that we've invited to enroll in this biorepository have consented to enroll. And again, with a program manager who can, like, meet the patient, give them a sample collection kit, get the kit and then bring it to our lab. It's sort of like a concierge service, which is amazing, but that lets us get all of these biospecimens. And then when they arrive in the lab, we process them to the point where, if it's a serum sample, we can plate the serum on a susceptible bacterial host, we can actually look for phage in the serum. All the other specimens that might have the bacterial pathogen we care about, we're plating it on selective media and then saving the bug.

    And this sort of biorepository that grows bigger with every patient that we treat with phage therapy is, I think, a fabulous resource for research. We're obviously limited in what we can say because each patient is in some ways unique in terms of the phages they're getting and their condition. And also like the dosing and formulation and the frequency and duration that they get phage.

    But nonetheless, right, as a hypothesis-generating exercise, we think that it's useful to collect what we can from these patients to fuel our research questions.

  35. Joe Campbell

    Yeah, and I guess that sort of leads to one of our other standard questions, which is, well, I forget. You said your first patient was 2020? And I mean, with all this, with all these sample collections and just thinking about it, what would you say has been your biggest lesson learned? And maybe we can talk more about, like, the dosing and the selection of phages.

    We've talked a lot about how you prep them. I mean, you could talk about that if you want, but maybe focusing a little bit more on, like, what you're actually gonna put into the patient. What has changed since 2020?

  36. Daria van Tyne

    Yeah, that's a good question. I would say the dose hasn't really changed. We also haven't really changed the routes. I've noticed an interesting sort of segregation in terms of opinions for patients with respiratory tract infections. There seem to be some in our field who think that patients should be treated with intravenous phage therapy for respiratory tract infection. There are others who think they should be treated with inhaled phage therapy.

    And those two camps are like, I would never do the other one. I think that's interesting. At Pitt, we just think more is more, and so for that kind of patient, we give them both IV and inhaled. And that might be overkill, and that may actually not be the right way to do it. But in the absence of data suggesting otherwise, we just give patients as much phage by as many different routes as we can.

    In the hopes that that's gonna have a therapeutic benefit for them. I think the way to answer those questions is obviously to do trials. And I think the trials that have been recently completed and that we're starting to read about now are usually trials that were designed like five years ago or more. So unfortunately, because it takes so long, so darn long to do a clinical trial, right?

    The data that we get from the trials today is useful, but it's only really useful for designing the next trial.

  37. Joe Campbell

    What?

  38. Daria van Tyne

    So I'm pretty excited about the next phase, like the next wave of trials that we haven't heard about yet, that are just starting now, because I think those are the ones, you know, those are gonna generate more relevant data. However, by the time we get the results, the field will have progressed maybe another three or four years, so it'll probably still feel outdated. And like these trials were designed by boneheads who didn't know what they were doing.

    because we know so much more now than we did then.

  39. Joe Campbell

    Well, there's a big difference between being, you know, ignorant and being dumb. I mean, obviously everyone does what they think is best given what they know. But I guess one thing about the different routes that you just mentioned, is there any anecdotal or maybe even real data about this? Are people measuring the generation of phage-neutralizing antibodies? I mean, I guess one argument against not doing both routes is that you might be more likely to generate phage-neutralizing antibodies.

    And do you look for that? And have you seen it?

  40. Daria van Tyne

    Yeah, we definitely look for it in the serum, you know, provided by patients enrolled in our biorepository. I think we see good evidence of neutralization of phage activity with plasma from patients that get IV phage, as long as the patients are immunocompetent. We also have done phage therapy in a fair number of solid-organ transplant patients who are immunosuppressed after their transplant, and the immune response to phage seems to be quite muted in those patients.

    And I think that's expected, given that they're immunosuppressed. It also might hint that that's a good population to do phage in, because they won't neutralize the phage as much as an immunocompetent person would. There's plenty of evidence, I think, from our own work in the lab, as well as in the literature, of serum neutralization of phage activity following IV phage administration. I'm writing a grant right now and so I'm looking at papers.

    And I think that there is at least one, if not a couple of papers, showing serum neutralization of phage activity following inhaled phage therapy. So it may not be the case that giving it by a different route won't generate a neutralizing response. I don't know about oral phage, I don't know about topical phage. You might think that, you know, those other routes may be less likely to generate, like a systemic neutralizing response to phage activity.

    Yeah, unfortunately, we have no idea what that even means, right? Like, how much neutralization would you need to see to get a therapeutic effect, right? There's also evidence, as we all know, that phage may help boost the immune response if it's the immune response directed to the pathogen and not to the phage. So this is a wide-open field. It's an exciting time, right? We can learn more about the immune system and how it responds to therapeutic phage.

    But it's like a research question right now, at least in my view, because we have no idea what any of that means clinically for patients that get phage therapy.

  41. Joe Campbell

    Yeah, I always get a little bit nervous when people seem to think they know the answer to any of these questions.

  42. Daria van Tyne

    I'm the first one to say I have no answers. I have a lot of questions, but I have no answers.

  43. Jessica Sacher

    On that note, like, you mentioned at the beginning, that you can't imagine one without the other anymore. Like the therapeutic phage-making in your lab and the research into it, like, are there, what are some cool projects that have you guys started because of what you've learned from treating the patients?

  44. Daria van Tyne

    Yeah, I guess, like when I'm writing research grants now, what I'm most excited about, or what I'm most interested in are, I mean, I guess three things. First is like the evolutionary aspect of treating a bacterial population with phage. And it goes across a couple of axes. The first one is like, how does phage activity differ in vitro when we measure it in the laboratory, when we're doing phage susceptibility testing versus like in the patient that's getting phage therapy?

    So the way I think about it right now is like we treat patients with cocktails of multiple phages. When those phages are exposed to susceptible bacteria, it's almost like a cage match, or like a gladiator situation, like, which phage is the winner? Is there a winning phage? What are the actual dynamics of like phage infection and replication of a bacterial population when you give a cocktail?

    So I'm interested in, like, doing those experiments in vitro, in the laboratory, to see, okay, if I treat, you know, a culture with a phage cocktail, is there a winning phage? Or do they all replicate? And then how does that compare with a patient that's getting that same phage cocktail? That's one thing. The immune response to phage is another big one, right?

    And there’s just so much that we don't know. So a patient’s serum neutralizes phage. Okay, what's the epitope? What's the actual interaction between the antibodies that are being made and the phage? And what does that mean for, you know, therapeutic efficacy? Those are all important research questions. And then the third one is, like, the impact on the microbiome. So if I treat a patient with phage, whether it's their respiratory microbiome or their GI microbiome,

    is there any signal that phage is doing anything to, you know, decrease the abundance of the pathogen in the microbiome, right? We say that phage therapy should be microbiome-sparing, but do we have any evidence of that? And so trying to generate that kind of evidence, both in the laboratory, but also in the patients that we're treating with phage therapy. Those are the questions that get me excited about research these days.

  45. Jessica Sacher

    And have you found, like, which phage susceptibility assays do you feel are the most representative of in vivo these days?

  46. Daria van Tyne

    I have no idea. I have no answers, but I share that question from a practicality standpoint. In the lab, we do soft agar overlay spot titering because it's like the most efficient way that we can move through the volume of requests that we get. For phage susceptibility testing in the absence of, like, known correlates of efficacy, right? We'll just use the most efficient method. I have a colleague who's actually like, dug into the literature to, like, be like, here are all the different susceptibility testing methods.

    Like, what are the pros and cons of each one? That’s to try and set us up to say, okay, can we design an in vivo experiment where we test these different methods against one another and see which one actually is going to predict the in vivo efficacy of phage? So I'm excited for that work to proceed.

  47. Jessica Sacher

    Very cool.

  48. Daria van Tyne

    I think that there's pros and cons to each one, you know, on the research side, we do liquid susceptibility testing as well. But for our like clinical phage screening, it's all soft agar overlay and just titering.

  49. Joe Campbell

    Since you have a lot of undergrads going through your lab, have you ever done an experiment which could be comforting or troubling, where you, like, have three different undergrads do the same assay on the same day, with the same phage and the same bug? I mean, and I guess, you know, for lack of a better term, maybe the term is robust. But like, you know, when we were at the DC phage meeting or Graham and Chip's meeting, or whatever you wanna call it, you know.

    Robin Patel was giving a talk about how she, and the people at, I guess that was the Army, were trying to get the same results in different labs with the same assay. So, if you give three undergrads, I don't know if you've done this experiment, you know, here's the same protocol. Do they get the same answer?

  50. Daria van Tyne

    Yeah, it's usually like a grad student and their undergrad, and I literally met with a grad student today and was talking about exactly that. We have found there's certainly variability. The soft agar overlay titer assay can be very variable. So it can depend on, like, how wet is your agar, or how close to the fan of the incubator did your plate get? Is it kind of dry on one half of the plate?

    That affects your interpretation of the result. What we tend to do is have, you know, two different people in the lab do the test. I should say this is on the research side. On the clinical side, we just don't have the capacity to test more than one time unless we suspect contamination or the results are unexpected. But on the research side, two people will do the test.

    And if they get the same result, then that's the result, and if they get different results, then we'll do the test a third time to try and break the tie. But that's any of these assays. There's variability within an assay, and then there's also variability between assays. So we know, as Robin Patel showed in that presentation, that if you test phage susceptibility with a liquid assay versus a plate-based assay, you may not get the same result for the same phage each time.

    And what we don't know is what any of that even means when we actually give a patient that phage for therapy. That's a big, big gap that we have right now.

  51. Joe Campbell

    Yeah, I mean, I guess, you know, a lot of us thought about antibiotics, and you know, as Robin also points out, there are the CLSI guidelines as to how to do antibiotics. And there's a real expectation that if you measure an MIC in California, it will be the same MIC you'll get in Pittsburgh, within a factor of two. Where do you think we are in the phage world broadly with that?

    If someone does the same assay in Pittsburgh and in California, will they get the same?

  52. Daria van Tyne

    Hm, that's a good question. I mean, I think there's hope that we will get there, but we're not really sure what the test should look like yet. And also we have to think about, like, if we would like phage to be more widely used, then we would want phage susceptibility testing to be performed in a clinical microbiology lab setting. And I don't think a clinical micro lab would ever do like a soft agar overlay spot titer test of phage susceptibility.

    It's just not gonna happen.

  53. Jessica Sacher

    Laborious.

  54. Daria van Tyne

    It's incredibly laborious, not to mention, just like the, you know, methods and technique involved. I think that the most appropriate future method should be some sort of liquid-based assay in a 96-well plate. But how that should be developed and how it should be deployed, I'm not really sure yet, but suffice to say, that's a big hurdle that the field faces right now.

  55. Joe Campbell

    Yeah, I remember well when I was a program officer and I had, you know, I'd listened to some Ebola talks and there was a huge deal that, you know, if you took, you know, cultured cells, like maybe HeLa cells or something, well, HeLa, I'm probably using the wrong example, but a cultured cell that you could just pull out the cell every time, you of course, got a more uniform answer as to what could inhibit Ebola growth.

    But then people were worried that, well, what you actually want is fresh cells, cause that's gonna be more relevant to the important cells that Ebola infects in a patient. But of course, those assays would be much more variable because you're starting with fresh cells every time. So, I mean, I guess it's just, I'm babbling, but it's sort of a, you know, it's a…

    It's a constant problem: The assay that is very reproducible might be less clinically relevant. And I guess everyone…

  56. Daria van Tyne

    Yeah, I don't think there's a an easy solution, but I think thinking about problems like that is how we work to make phage therapy more like accessible and more widely used, right? Like, I don't think anybody's gonna have a magic solution to it. But I think acknowledging this problem and then trying to develop solutions for it. I mean, the, you know, the NIH hopefully will have these centers for phage therapy, phage research centers through a P01 mechanism.

    And part of the mission of that funding mechanism, when it was designed, was to develop like methods, models, and assays to facilitate the development. So, you know, if any of those centers actually come to light and get any sort of funding, that could be a mechanism or a manner to sort of develop those kinds of assays and tools. That would be nice.

  57. Joe Campbell

    Yeah, we all have our fingers crossed on that one.

  58. Jessica Sacher

    So we should probably wrap up soon.

    If you wanna get to our kind of mini lightning round questions.

    Happy ending.

  59. Joe Campbell

    I think we should. The “Where do you hope to be in five years, and where do you hope to be in 15 years?” question.

  60. Jessica Sacher

    Yeah. Regarding both, I would say the phage therapy treatment and just your lab as a whole, and how the research dovetails in. I think that's a really cool angle.

  61. Daria van Tyne

    Yeah, I mean, I hope in five years that we're still in business, that I still have a research lab.

    You know, I guess a year ago I wouldn't have considered the possibility that I wouldn't, but now I think I have to consider the possibility that I wouldn't be in business anymore. Five years in the future. For phage therapy, I am hopeful that clinical trials that are wrapping up now, right, will show promising results. I don't think anybody's results are going to be like, amazing and fabulous, but I'm hoping that we're not gonna see a bunch of negative results and that those trials will generate more momentum to keep going.

    And keep doing this and trying to keep developing phage therapy. It would be great if in five years there were an FDA-approved product, like an FDA-approved phage cocktail to use in people. I think that might be a little optimistic, but you know, if we're going to continue developing phage therapy, then I would hope that at least by 15 years from now we have FDA-approved phage therapies.

    But I also think that compassionate use phage therapy is not gonna go anywhere, right? There's always going to be people who aren't gonna be eligible for a clinical trial, or whose doctor wouldn't want to treat them off-label with an available phage cocktail. And so I think that there's always gonna be people that could stand to benefit from compassionate use phage therapy. So, whereas, you know, a couple years ago I thought maybe more that, like, we would just do clinical trials and just treat people with, like, off-the-shelf phages.

    I now think that the two are likely to coexist for a while.

  62. Jessica Sacher

    Yeah, I do, too. It's like the long tail needs to be addressed with the personalized mechanism. And maybe we transition it out of calling it compassionate use one day. And instead, it's just a personalized kind of avenue for phage therapy that still has sort of like checks and balances as you move away from it being, like, an urgent, emergency tomorrow thing.

    Like, there's already been so much progress in the shift to like, okay, a 30-day thing, like it's a little bit more routine, and yeah, we can prepare a little bit. So I hope that it continues like that.

  63. Joe Campbell

    And I guess at least one more question from me, other than what you already alluded to with the fact that science funding is in an interesting place in the US. Beyond that, what are the things that you see as stopping, not allowing the goals that you talked about from happening?

  64. Daria van Tyne

    I think the one thing I would say is, I mean, I think I've gotten as far as I have in phage therapy because of the generosity of the community. So, like, the first cases of patients that we treated with phage were not our phages. They were, you know, gifted to us from other researchers who, you know, saw their value, not their monetary value, but saw their value for human health and improving human health.

    And wanted to make them available if they had a potential role in improving somebody's health. And as I've gotten further and further into phage, right? I've just been, like, really astounded in a good way by how generous and cooperative the community has been. And I think that's why I'm sort of like, telling people, nobody's gonna make money on phage, because I'm afraid that, like, you know, venture capitalists will come in and they'll…

    We'll turn on each other and start to get really like, selfish and greedy and not share and play well together anymore. That would be my biggest fear, right? Would be that egos take over and people stop sharing.

  65. Joe Campbell

    Yeah, I mean, the other thing I've heard some companies have told me, you know, not really because of venture capitalists, but because, like, if you have a phage that's gonna be used in a clinical trial and you were to give it to someone compassionately and something adverse were to happen, it could put a hold on the clinical trial, which I guess, you know, it's still a little bit of a monetary reason for not doing it, but it's maybe a more understandable monetary reason anyway.

  66. Daria van Tyne

    Yeah, the flip side of that's also true, though. So, like, we are doing a clinical trial of Achromobacter-targeting phages, and some of the phages that we are using in the clinical trial, we've already given to patients under compassionate use and haven’t seen any safety signal. And having those phages, you know, be safe and well tolerated in those patients, we pointed to that data in support

  67. Joe Campbell

    Yeah, that's a good point, of course.

  68. Daria van Tyne

    when we're talking about the clinical trial. So I guess that it just goes both ways.

  69. Joe Campbell

    Well, you know, I will say, and thank you for all your time. And you were talking about the generosity of everyone. You were very generous with your time today. And in doing this podcast, I think Jessica and I have experienced that too. I don't think anyone has told us they wouldn't do it.

    So it's been great. We've had a lot of really interesting conversations, and we did again today.

  70. Jessica Sacher

    That is true.

    Yeah, we're always the people who…

  71. Joe Campbell

    Jess, could you have anything else to add?

  72. Jessica Sacher

    say no. I would say we're like, no one has any time, no one has time for another Zoom call. But we hope that we can help share this widely and that it makes it worth it, because people just, yeah, they love getting into the nitty gritty in this kind of format, I think. And yeah, I really appreciate your time and all the tangible tidbits that you are so open with.

    So, yeah.

  73. Daria van Tyne

    Yeah, it's been great. I mean, we're all just a bunch of nerds that like talking about phage, so any opportunity to talk to people about phage, of course, we're gonna take it.

  74. Jessica Sacher

    Yeah, I love it.